# V1 Empirics Check — openai/gpt-5.4 (Variant C)

**Model:** openai/gpt-5.4
**Variant:** C
**Date:** 2026-03-30T16:45:36.009370

---

## 1. Idea Fidelity

The paper only partially pursues the original idea in the manifest, and it misses several of the strongest elements of that design.

Most importantly, the manifest was built around **municipality-level staggered adoption** of Seguro Popular, with 342/524/946/1,600 municipalities entering in 2002–2005. The paper instead analyzes a much coarser **state-level rollout**, assigning a single treatment date to all municipalities in a state. That is a major departure. It throws away the most compelling source of identification, reduces variation sharply, and makes the empirical design much less persuasive. Relatedly, the manifest proposed using the universe of roughly **2,400+ municipalities**; the paper uses **1,404 municipalities**, mainly because of a mortality-based sample restriction induced by denominator problems.

Second, the paper does not deliver several core pieces of the proposed design: no municipality-level treatment intensity, no event-study figures, no Sun-Abraham comparison, no triple-difference amenable vs. non-amenable specification, no HonestDiD sensitivity analysis, and no meaningful mechanism evidence. The manifest’s most attractive feature was that cause-specific decomposition would be embedded in a richer staggered-adoption design; here, the decomposition remains, but the broader design is much weaker than advertised.

Third, the paper changes the outcome construction in a consequential way. The manifest anticipated using CONAPO live-birth denominators, possibly supplemented by birth registrations. The paper instead constructs births from **total deaths times national crude rates**, which is not a minor implementation detail but a substantive redefinition of the outcome. That choice creates a serious measurement and endogeneity problem that is central to the credibility of the estimates.

## 2. Summary

This paper asks whether Mexico’s Seguro Popular reduced infant mortality from causes plausibly responsive to medical care. Using death microdata and a Callaway-Sant’Anna staggered DiD, it finds a negative but imprecise effect on amenable infant mortality, near-zero effects on non-amenable causes, and no effect on overall infant mortality.

The topic is important and the cause-of-death decomposition is potentially valuable. But in its current form, the paper does not deliver a clear or economically meaningful result, mainly because treatment timing is too coarsely measured, outcome denominators are constructed in a problematic way, and the paper leans too heavily on patterns in point estimates that are statistically and substantively fragile.

## 3. Essential Points

1. **The denominator construction is not credible enough for the main specification.**  
   Estimating municipal births from municipal total deaths times national CBR/CDR is not “classical measurement error,” and the paper’s claim that it merely attenuates coefficients is incorrect. Municipal total deaths are themselves affected by age structure, disease environment, migration, and potentially health policy; they are not a clean population proxy. Worse, infant deaths contribute mechanically to total deaths, so the denominator is partly constructed from the numerator. This can induce spurious correlation and unstable rates, especially in small municipalities. You need either (i) actual municipal births, (ii) a defensible external population/birth denominator, or (iii) a count model with an external exposure measure. As written, this is the paper’s biggest credibility problem.

2. **Treatment is mismeasured relative to the institutional rollout, weakening identification substantially.**  
   The paper treats Seguro Popular as a state-level adoption beginning in 2002–2005. But the policy rolled out within states across municipalities, and the original idea rightly emphasized that margin. Collapsing to state timing discards identifying variation and risks substantial timing misclassification. Given that standard errors are clustered at the state level and treatment varies only at that level, the design is much closer to a 32-cluster state-policy study than to a municipality-level staggered design. You need to recover municipality enrollment timing or, if impossible, reframe the paper as a state-level policy evaluation and be much more cautious.

3. **The paper overinterprets a non-result.**  
   The main estimate is small in magnitude and far from precise: \(-0.269\) amenable deaths per 1,000 births relative to a mean of 11.3, with SE 0.313. That is not a meaningful reduction in infant mortality by the standards of major insurance expansions, and the confidence interval is wide enough to include both modest benefits and no effect. The “pattern” that amenable is negative and non-amenable is near zero is suggestive, but it is not enough. You need a formal test of the difference between amenable and non-amenable effects, dynamic pre-trends by cause group, and a much more restrained interpretation. In the current draft, the conclusions outrun the evidence.

## 4. Suggestions

The paper has a good question and a potentially publishable angle, but it needs a more serious empirical rebuild. My suggestions below are mostly aimed at making the design believable and the result interpretable.

First, **go back to the treatment data**. The paper would improve dramatically if you implemented the municipality-level rollout envisioned in the manifest. That is the right unit institutionally and econometrically. If municipality enrollment dates exist in administrative reports or can be reconstructed, use them. If only state-level adoption is truly available, then simplify the paper and present it honestly as a state-level staggered policy study. In that case, I would strongly recommend collapsing the analysis to the state-year level as a robustness check, because with treatment assigned at the state level and only 32 clusters, municipality-level precision can be misleading even if you cluster correctly.

Second, **fix the birth denominator issue before anything else**. The current rate construction is too problematic for a flagship result. At minimum, do the following:
- Use **registered births** wherever possible, even if coverage is imperfect, and show how results compare.
- Use **CONAPO municipal population projections** directly if available, rather than backing population out of deaths.
- Report results for **infant death counts** and **neonatal death counts** using Poisson or quasi-Poisson models with an offset for births/population where feasible.
- Show that the treatment does not affect the denominator itself. Right now, that is an unaddressed concern.
- If you must use the constructed denominator, validate it aggressively against observed births in years where birth data overlap.

Third, the paper needs a more careful discussion of **magnitudes**. A reduction of 0.269 per 1,000 births is only about 2.4 percent of the pre-treatment amenable mean and roughly 1.5 percent of overall IMR. For a program of this scale, that is small. It may still be policy relevant, but then the paper should explain why one should expect only a small mortality effect: partial take-up, limited supply response, weak quality of care, already declining mortality, or treatment dilution because assignment is based on state entry rather than actual household enrollment. Right now, the paper implicitly markets the estimate as substantively important without doing the economic interpretation.

Relatedly, the estimate for **neonatal mortality** is actually positive and imprecise, while the paper argues that perinatal conditions drive the effect. That combination is not impossible, but it needs explanation. If perinatal deaths are falling, why is neonatal mortality not? One possibility is coding shifts between neonatal and post-neonatal causes, or denominator noise. Another is that the cause-specific result is simply unstable. I would want to see cause-specific effects separately for neonatal and post-neonatal mortality.

Fourth, the paper should improve its handling of **inference**. Clustering at the state level is directionally right because treatment varies at that level, but with 32 clusters and only four adoption cohorts, asymptotic clustered standard errors are not enough. You should add:
- **wild-cluster bootstrap** p-values,
- **randomization inference / permutation tests** based on cohort assignment if feasible,
- and a discussion of how much of the identifying variation is effectively cross-state rather than cross-municipality.

I would also like to see the **event-study plots** that the paper references conceptually but does not show. For this design, the plots matter more than the pooled ATT. Show them for overall IMR, amenable mortality, non-amenable mortality, and perinatal mortality. If pre-trends are noisy, say so. If they are non-flat, that is crucial information.

Fifth, the “built-in placebo” idea is useful, but it is currently overstated. Congenital anomalies are not a perfect placebo: while insurance does not prevent chromosomal anomalies, better prenatal and neonatal care can affect survival conditional on anomaly, and coding may change with hospital delivery. External causes are also a strange placebo for infant mortality because they are rare and noisy. I would suggest:
- using the placebo language more cautiously,
- formally testing **amenable minus non-amenable** as a within-municipality contrast,
- and considering a stacked or triple-difference design at the cause-group level.  
That would be closer to the manifest and much more convincing than comparing two separately insignificant coefficients in levels.

Sixth, the sample restriction excluding municipalities with fewer than 50 mean annual deaths needs more justification. This is a huge share of municipalities, and it changes the estimand toward larger places. You should show:
- how excluded municipalities differ,
- whether treatment timing differs systematically for excluded places,
- and whether weighting by births or population changes results.  
In a public-health paper, dropping smaller and poorer municipalities can be consequential, especially when those are precisely the places where insurance expansions may matter most.

Seventh, I would be more disciplined about **language and framing**. Terms like “What Saves Infants?” and claims that the decomposition “reveals” an effect are too strong for the evidence presented. The paper’s current contribution is narrower: it provides suggestive evidence that any mortality effect, if present, is more likely to appear in causes plausibly responsive to care than in congenital or accidental causes. That is a respectable result if carefully presented. It is not yet evidence that Seguro Popular saved infants in any clear aggregate sense.

Finally, the paper would benefit from one or two **mechanism checks**, even simple ones. The manifest mentioned institutional delivery, prenatal care, and catastrophic spending. You do not need a full second paper, but one descriptive or reduced-form mechanism result would help anchor the interpretation. If Seguro Popular truly reduced perinatal mortality, I would expect some movement in institutional delivery, prenatal care utilization, skilled birth attendance, or neonatal care capacity. Without that, the cause-specific story feels somewhat reverse-engineered from noisy estimates.

In short: the question is strong, the decomposition is promising, and the null effect on non-amenable causes is at least directionally reassuring. But the current empirical implementation is not yet at AER: Insights standard. If you can recover municipality-level treatment timing and replace the denominator construction with something defensible, the project would improve substantially. Without those changes, the paper remains suggestive but not convincing.
